Lupin Limited (500257) Fair Value & Analysis
Other · IN · Market cap ₹946B
Fair value as of: Aug 13, 2026
From 24 valuation models · updated 4 days ago
Share price −8.8% over the past month.
A solid business, but screening 12% overvalued on our models.
What matters now
- A fairly wide model range (₹1,267 to ₹2,506) leaves room in how you read the outcome.
- Our model range runs from ₹1,267 (bear) to ₹2,506 (bull), base ₹1,983. The closer the price sits to the lower half, the larger the margin of safety.
- Quality 70/100 (solid quality) with high evidence: the data supports the verdict.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.
How to read this chart
60‑month range ₹577.99 – ₹2,476 · fair‑value band ₹1,267 – ₹2,506 · the ₹2,259 price screens above the ₹1,983 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 13, 2026.
Analysis
Lupin Limited (500257) currently trades at ₹2,259, while our model-based Fair Value estimate is ₹1,983, implying the stock looks roughly 12.2% overvalued today. The Quality Score stands at 70/100 (solid quality), in the Other sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Net debt stands at ₹17.4B. The stock trades on a trailing P/E of 28.3 (as of Jul 4, 2026). Fundamentals as of Aug 13, 2026
Our scenario range runs from ₹1,267 (bear case) to ₹2,506 (bull case); at ₹2,259, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 9% below its 52-week high and 23% above its 52-week low. For context, the median of 10 Other peers we cover trades at -52% fair-value upside, at -12%, 500257 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 24 models by family
Widest divergence: DCF Models (₹2,744) versus Asset-Based (₹359.10). Highest evidence: Growth DCF (80).
Notify me when 500257 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 72 · Market factors (momentum, volatility) 61
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Lupin Limited, a pharmaceutical company, develops, produces, and markets a range of branded and generic formulations, biotechnology products, and active pharmaceutical ingredients (APIs) worldwide.
Full company description
Lupin Limited, a pharmaceutical company, develops, produces, and markets a range of branded and generic formulations, biotechnology products, and active pharmaceutical ingredients (APIs) worldwide. It offers formulations for use in the therapeutic areas of cardiovascular, diabetology, asthama, pediatrics, central nervous system (CNS), gastro-intestinal, anti-infectives, nonsteroidal anti inflammatory drug therapy, anti-TB, and cephalosporins. The company also develops drug delivery technologies; and offers biosimilars for various therapies, such as oncology, anti-inflammatory, anti-virals, rheumatoid arthritis, endocrinology, diabetes, ophthalmology, and women?s health. In addition, it engages in the novel drug discovery and development programs for use in the treatment of CNS disorders, oncology, immunology, pain, and metabolic disorders. The company was formerly known as Lupin Chemicals Limited and changed its name to Lupin Limited in 2001 as a result of its amalgamation with Lupin Laboratories Limited. Lupin Limited was founded in 1968 and is based in Mumbai, India.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Lupin Limited reported revenue of ₹275B in FY2025 versus ₹164B in FY2021, a compound +13.8%/yr. Reported net income was ₹53.3B in FY2025.
500257 screens 12% overvalued. Compare with Federal Home Loan Mortgage Corporation →
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Other stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Federal Home Loan Mortgage Corporation FREJO | $15.58 | $51.90 | +233% |
| 533278 533278 | ₹409.15 | ₹660.78 | +62% |
| Nestl?? India Limited 500790 | ₹1,497 | ₹191.93 | -87% |
| ITC Limited 500875 | ₹279.50 | ₹212.74 | -24% |
| Wipro Limited 507685 | ₹183.80 | ₹193.38 | +5% |
| 540376 540376 | ₹4,054 | ₹1,542 | -62% |
| 540777 540777 | ₹537.50 | ₹149.72 | -72% |
| Dabur India Limited 500096 | ₹413.80 | ₹122.93 | -70% |
| 540719 540719 | ₹1,835 | ₹872.41 | -52% |
| Britannia Industries Limited 500825 | ₹5,626 | ₹1,289 | -77% |
Compare Lupin Limited with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
Frequently asked questions
Is Lupin Limited (500257) overvalued or undervalued?
What is the fair value of 500257?
What is the quality score of 500257?
What is the net profit margin of 500257?
Does Lupin Limited pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Lupin Limited and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.